Nrf2, a transcription factor that regulates inducible expression of detoxifying enzymes, is critical in preventing N-nitrosobutyl(4-hydroxybutyl) 
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Introduction
The urinary bladder is exposed to many water-soluble chemicals, thus this tissue is highly susceptible to tumorigenesis that arises from water-soluble carcinogens. N-nitrosodibutylamine was first identified as a rat bladder carcinogen (1) , and is also considered carcinogenic to human (2) . Although concentrations are generally low, N-nitrosodibutylamine has been detected in tobacco smoke, corrosion inhibitors, foods and rubber products. Metabolism of N-nitrosodibutylamine occurs primarily in liver, and tumor formation in rat bladder is dependent on the generation of the w-oxidized metabolite, N-nitrosobutyl (4-hydroxybutyl) amine (BBN; ref.
3). Oral administration of BBN to rodents induces cancer specifically in urinary bladder (4) .
BBN itself is either activated by alcohol/aldehyde dehydrogenase-mediated oxidation to yield
N-nitrosobutyl(3-carboxypropyl)amine (BCPN), or detoxified by
UDP-glucuronosyltransferase-catalyzed conjugation to form BBN-glucuronide (5) . BCPN and BBN are chemically cleaved to their respective alkylcarbonium ions and bind covalently to DNA (6) . Furthermore, BCPN itself has been shown to have carcinogenic effects on urothelial cells (7) . Conversely, BBN glucuronidation in the liver suppresses carcinogenesis in the urinary bladder by decreasing urinary BCPN concentrations (8) .
Mutations in p53 are one of the most common genetic lesions found in human cancer, with over 50% of tumors examined having a single or compound mutation or deletion in the p53 gene (9) . In bladder cancer, a single G to A transition mutation in the CpG-island of p53 accounts for ４ accumulation of mutant p53 is directly associated with a decreased survival rate (11, 12) , and loss of a p53-bearing chromosome is an early indication of CIS progression and malignancy (13) . In stark contrast, p53 mutations are detected in only 3% of low-grade, superficial papillary tumors (14) .
Alterations in the p53 gene are also associated with carcinogenesis in rodent models.
Homozygous p53-knockout mice are viable, but highly susceptible to spontaneous tumorigenesis, particularly lymphomas, at an early age. is not known whether these mechanisms overlap or are independent pathways, and whether the protection is synergistic or additive in nature. To address these issues we generated an
Nrf2
-/-::p53 +/-double mutant mouse line and attempted to determine whether Nrf2-deficiency further accelerates urinary bladder carcinogenesis in p53-deficient mice and whether there are unique interactions between the Nrf2 and p53 pathways.
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Materials and methods
Reagents
BBN was from Tokyo Kasei Co. (Tokyo). UDP-glucuronic acid (UDPGA) was purchased from Sigma (St. Louis). BCPN was prepared as previously described (23) .
Animals
A colony of Nrf2-null mice on an ICR/129SV background (22) 
BBN-induced bladder carcinogenesis
A 0.05% concentration of BBN was dissolved in H 2 O, and was supplied ad libitum for eight weeks in dark-colored bottles. After this experimental period, the mice were analyzed.
Urinary bladders were inflated, and then fixed in 10%-buffered formalin. Each bladder was sectioned sagittally and each cup-shaped area was cut into four pieces. These eight strips of bladder tissue were serially embedded in a single paraffin block, cut into thin sections, and stained with hematoxylin and eosin. Bladder lesions were histologically diagnosed according to the criteria of Oyasu et al. (24) .
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RNA blot analysis
Total RNA from whole urinary bladders was extracted with Isogen (Nippon Gene, Toyama).
RNA (10 mg) was separated by 1.5% agarose gel electrophoresis containing 2.2 M formaldehyde and transferred to a nylon membrane. Mouse cDNA probes for UGT1A6 and NQO1 are described respectively (8, 25) , and GSTP1 cDNA was kindly provided by Dr. Kimihiko Satoh.
p53-target genes were amplified by RT-PCR, using mouse liver RNA as a template. The primer 
Measurement of BBN-glucuronide in vitro
The protocol for measuring BBN-glucuronide activity in mouse liver has been previously described (8) . Briefly, microsome fractions were prepared from mouse liver as described (27) .
A typical reaction mixture consisted of 100-mM potassium phosphate buffer (pH 7.4), 1-mM BBN, 5-mM UDPGA, 0.05% Brij58, and microsome preparation (600-μg protein) in a final ９ volume of 1 ml. Reactions were initiated by the addition of BBN, and incubations were performed at 37°C for 30 min. BSA (1 mg) and 24 % TCA (0.1 ml) were added to the incubation mixture to terminate the reaction. After centrifugation at 10,000 x g for 5 min, the supernatant (0.1 ml) was injected into the HPLC as described above. Separation of BBN and BBN-glucuronide was accomplished using a mobile phase consisting of a 2:8 mixture (v/v) of acetonitrile and 20-mM sodium acetate buffer (pH 4.5) at a flow rate of 1 ml/min.
Statistical analyses
Data were expressed as the mean ± standard error (SEM). The Student's t test was used to determine the statistical difference among groups. The values for urinary bladder incidence were analyzed using the χ 2 or Fisher's exact probability test. A P value of less than 0.05 was considered statistically significant.
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Results
Higher susceptibility of Nrf2 -/-::p53 +/-mice to BBN-induced carcinogenesis
In order to clarify whether Nrf2 and p53 cooperatively function in protection against chemical carcinogenesis, we examined the susceptibility of Nrf2 -/-::p53 +/-mice to BBN-induced urinary bladder tumor formation. Figure 2A ). Nrf2 -/-mice had higher urinary BCPN concentrations than wild-type mice, but BCPN concentrations in p53 +/-mice were not altered substantially from wild-type mice ( Figure   2A ). Basal BBN glucuronidation activity was significantly lower in the hepatic microsomes from Nrf2 -/-mice, but not p53 +/-mice, which correlates well with previous observations of decreased glucuronidation in the Nrf2 -/-mouse liver (8) .
Expression of p53-and Nrf2-target genes in the urinary bladder after BBN treatment
To elucidate the role that p53 plays in attenuating BBN carcinogenesis, we examined the expression of p53-target genes, p21, MDM2 and Bax, in the urinary bladder after BBN treatment.
Wild-type mice were treated with 0.0025%, 0.005%, 0.0075% or 0.01% BBN in the drinking water for two weeks, and mRNA levels of the p53-target genes were examined by RNA blotting.
Expression of p21, MDM2 and Bax was increased in a BBN-dose dependent manner ( Figure 3A ).
The increase in p21 was especially marked, with expression increasing approximately 10-fold after 0.01% BBN treatment, and MDM2 and Bax expression increasing approximately 4-fold.
１２
Expression of these p53-target genes also increased in a time-dependent manner after 0.0075% BBN treatment, up to 14 days ( Figure 3B ). These results suggest that the BBN-treatment activates the p53 pathway through formation of the BBN-induced DNA damage. However, mRNA expression of NQO1, a typical Nrf2-target gene, was not affected by the BBN treatment (data not shown), indicating that Nrf2 was not activated by the BBN administration.
Expression of p53-and Nrf2-target genes in the Nrf2 -/-::p53 +/-urinary bladder
Considering that p53 and Nrf2 seemingly protect from urinary bladder carcinogenesis, we aimed to determine whether crosstalk exists between these two pathways. To this end, mice were treated with 0.0075% BBN for two weeks, and mRNA expression levels of Nrf2-and p53-target genes were examined. BBN-inducible expression of p21, MDM2 and Bax mRNAs all decreased in p53 +/-mice compared to those in wild-type mice, although the decrease in Bax expression was not statistically significant ( Figure 4A ). By contrast, p21 expression was modestly increased in Nrf2 -/-mice by approximately two-fold, and although the expression of MDM2 and Bax showed modest increases, neither was statistically significant. In Nrf2 -/-mice, UGT1A6 and NQO1 mRNA expression significantly decreased by 50% and 90%, respectively, compared with wild-type mice ( Figure 4B ). UGT1A6 and NQO1 expression in p53 +/-mice significantly increased by approximately 1.4-and 1.7-fold, respectively, compared to those in wild-type mice after BBN exposure. However, in Nrf2 -/-::p53 +/-mice this increase was not observed, suggesting that the increased induction is Nrf2-dependent ( Figure 4B ).
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Discussion
The current study aimed to determine whether there are interactions between the Nrf2 and p53 regulatory pathways that prevent carcinogenesis. The number of total carcinomas and invasive cancers were both increased in Nrf2 -/-::p53 +/-mice compared to mice bearing either Nrf2 -/-or p53 +/-mutation alone. As has been previously reported, the primary role of Nrf2 in the protection of BBN-induced carcinogenesis is to regulate BBN detoxification genes such as UGTs.
In addition, Nrf2 regulates antioxidant genes such as GCLC and GCLM, thereby aiding in oxidative stress prevention during carcinogenesis. Conversely, p53 acts to regulate cell proliferation, apoptosis, and DNA repair upon BBN exposure. The results of this study support our contention that these two pathways work cooperatively to protect the bladder from BBN-induced carcinogenesis.
The incidence of invasive carcinoma increased in Nrf2 -/-::p53 +/-mice compared to p53 +/-mice, demonstrating the presence of an additive pathological effect when expression of both factors was disrupted. Indeed, the ratio of invasive vs. non-invasive carcinoma was increased from 1.00 to 2.25 (Table 1) . Recent reports also suggest that in p53 knockout mice, increased formation of reactive oxygen species (ROS) occurs, demonstrating that Nrf2 and p53 both have a role in cellular protection from oxidative stress (28) . Similarly, formation of ROS seemingly aids in carcinogenic progression (29, 30) , thus it is probable that in bladder epithelia from Nrf2 -/-::p53 +/-mice the increased incidence of invasive carcinoma is due to higher levels of ROS.
We summarized this notion in Figure 5 .
Mutagenic or allelic loss of p53 correlates well with the incidence of urinary bladder carcinogenesis in rodent models (12) . In this study, we demonstrated that p53 target gene expression was induced in urinary bladder by BBN in a dose-and time-dependent manner, and Table 1 ). The activated p53 pathway in Nrf2 -/-mice may decrease the ratio of invasive cancer by increasing apoptosis or cell cycle arrest ( Figure 4A ). Therefore, it seems plausible that the decrease of p53 activity in conjunction with Nrf2 knockout lead to the increased incidence of invasive cancer in Nrf2 -/-::p53 +/-mice.
The expression of NQO1 was increased by BBN treatment in p53 +/-mice, but not in wild-type mice (data not shown and Figure 4B ). On the other hand, we previously demonstrated that UGT1A6 expression was decreased by BBN exposure (8) . The expression of UGT1A6 in p53 +/-was increased compared to that in wild-type mice after BBN exposure ( Figure 4B ).
Showing agreement with this observation, it was recently reported that p53 suppresses Nrf2-dependent expression of NQO1 and xCT (a component of the cysteine/glutamate exchange transport system) genes in a few culture cell lines (32) . The latter observation further supports our contention that the Nrf2 and p53 regulatory pathways interact. Whereas the precise mechanisms of how p53-mediated apoptotic response and the Nrf2-mediated antioxidant response remains to be clarified, both pathways seem to function together in cancer chemoprevention.
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One plausible explanation for this crosstalk of p53 and Nrf2 during cancer chemoprevention could be due to phosphorylation and activation of PKCδ by the ATM/c-Abl DNA repair and cell cycle regulatory pathways in response to BBN-induced genotoxic stress (33) . Because p53 +/-mice suffer from increased DNA damage due to reduced DNA repair capacity, activation of Nrf2-target genes by BBN may be caused by PKCδ in response to rising levels of DNA damage.
A previous study demonstrated strong correlation between PKCδ activity and Nrf2 activation in osteoblasts derived from ATM or c-Abl deficient mice, but a firm relationship between the two factors has not been established (34) .
In conclusion, our study demonstrates that the Nrf2 regulates expression of genes to repair DNA damage and to induce apoptosis. In Nrf2 -/-mice, elevated urinary BCPN concentrations lead to higher levels of DNA damage and enhance p53 activation. In p53 +/-mice, the failure to instigate DNA damage repair may lead to Nrf2 activation via the ATM pathway. Elevated levels of ROS in Nrf2 -/-or p53 +/-mice may contribute to increased incidence of carcinogenesis and tumors. 
